# Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC

> **NCT03371992** · EARLY_PHASE1 · UNKNOWN · sponsor: **Nilogen Oncosystems** · enrollment: 25 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DIAGNOSTIC_TEST:** 3D-EX
- **OTHER:** Evaluation of Response by RECIST

## Key facts

- **NCT ID:** NCT03371992
- **Lead sponsor:** Nilogen Oncosystems
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-09
- **Primary completion:** 2020-12
- **Final completion:** 2021-06
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2020-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03371992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03371992, "Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03371992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*